Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States
Sonoma Pharmaceuticals (Nasdaq: SNOA) has announced a distribution agreement with a leading global healthcare distributor for its wound care products in the United States. The partnership will leverage the distributor's extensive network of hospital systems and healthcare channels to expand Sonoma's wound care business across the country.
Sonoma's products are based on their patented Microcyn® technology, which uses stabilized hypochlorous acid (HOCl) for various applications including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care. CEO Amy Trombly described the partnership as a "huge step forward" for the company's U.S. wound care business expansion.
Additional details about the agreement can be found in Sonoma's Current Report on Form 8-K filed with the SEC on August 21, 2024.
Sonoma Pharmaceuticals (Nasdaq: SNOA) ha annunciato un accordo di distribuzione con un importante distributore globale di prodotti sanitari per i suoi prodotti per la cura delle ferite negli Stati Uniti. Questa collaborazione sfrutterà l'ampia rete di sistemi ospedalieri e canali sanitari del distributore per espandere l'attività di Sonoma nel settore della cura delle ferite in tutto il paese.
I prodotti di Sonoma si basano sulla loro tecnologia brevettata Microcyn®, che utilizza acido ipocloroso stabilizzato (HOCl) per varie applicazioni tra cui la cura delle ferite, la cura degli occhi, orale e nasale, le condizioni dermatologiche, la podiatria e la salute animale. Il CEO Amy Trombly ha descritto la partnership come un "enorme passo avanti" per l'espansione dell'attività di cura delle ferite di Sonoma negli Stati Uniti.
Ulteriori dettagli sull'accordo possono essere trovati nel Rapporto Attuale di Sonoma sul Modulo 8-K depositato presso la SEC il 21 agosto 2024.
Sonoma Pharmaceuticals (Nasdaq: SNOA) ha anunciado un acuerdo de distribución con un destacado distribuidor global de atención médica para sus productos para el cuidado de heridas en los Estados Unidos. La asociación aprovechará la extensa red de sistemas hospitalarios y canales de atención médica del distribuidor para expandir el negocio de cuidado de heridas de Sonoma en todo el país.
Los productos de Sonoma se basan en su tecnología patentada Microcyn®, que utiliza ácido hipocloroso estabilizado (HOCl) para diversas aplicaciones, incluyendo el cuidado de heridas, cuidado ocular, cuidado oral y nasal, condiciones dermatológicas, podología y cuidado de la salud animal. La CEO Amy Trombly describió la asociación como un "gran paso adelante" para la expansión del negocio de cuidado de heridas de la compañía en EE. UU.
Los detalles adicionales sobre el acuerdo se pueden encontrar en el Informe Actual de Sonoma en el Formulario 8-K presentado a la SEC el 21 de agosto de 2024.
소노마 제약(Sonoma Pharmaceuticals, Nasdaq: SNOA)는 미국의 상처 치료 제품에 대해 글로벌 선도 헬스케어 유통업체와 유통 계약을 체결했다고 발표했습니다. 이번 파트너십은 유통업체의 광범위한 병원 시스템 및 헬스케어 채널 네트워크를 활용하여 소노마의 상처 치료 사업을 전국적으로 확장할 계획입니다.
소노마의 제품은 마이크로신®이라는 특허 기술을 바탕으로 하고 있으며, 안정화된 차아염소산(HOCl)을 사용하여 상처 치료, 눈, 구강 및 비강 치료, 피부 질환, 발 치료 및 동물 건강 관리 등 다양한 용도로 사용됩니다. CEO 에이미 트롬블리(Amy Trombly)는 이번 파트너십을 회사의 미국 상처 치료 사업 확장을 위한 "거대한 진전"이라고 설명했습니다.
이번 계약에 대한 추가 세부정보는 2024년 8월 21일 SEC에 제출된 소노마의 8-K 양식 현재 보고서에서 확인할 수 있습니다.
Sonoma Pharmaceuticals (Nasdaq: SNOA) a annoncé un accord de distribution avec un important distributeur de soins de santé mondial pour ses produits de soins des plaies aux États-Unis. Le partenariat tirera parti du vaste réseau de systèmes hospitaliers et de canaux de santé du distributeur pour développer l'activité de soins des plaies de Sonoma à l'échelle nationale.
Les produits de Sonoma sont basés sur leur technologie brevetée Microcyn®, qui utilise de l'acide hypochloreux stabilisé (HOCl) pour diverses applications, y compris les soins des plaies, les soins des yeux, la santé bucco-nasale, les affections dermatologiques, la podologie et les soins de santé animale. La CEO Amy Trombly a décrit ce partenariat comme un "énorme pas en avant" pour l'expansion du secteur des soins des plaies de l'entreprise aux États-Unis.
Des détails supplémentaires sur l'accord peuvent être trouvés dans le rapport actuel de Sonoma sur le formulaire 8-K déposé auprès de la SEC le 21 août 2024.
Sonoma Pharmaceuticals (Nasdaq: SNOA) hat eine Vertriebsvereinbarung mit einem führenden globalen Gesundheitsvertriebspartner für seine Wundpflegeprodukte in den Vereinigten Staaten bekannt gegeben. Die Partnerschaft wird das umfangreiche Netzwerk des Distributors mit Krankenhaus-Systemen und Gesundheitskanälen nutzen, um das Wundpflegegeschäft von Sonoma im ganzen Land auszubauen.
Die Produkte von Sonoma basieren auf der patentierten Microcyn®-Technologie, die stabilisierte hypochlorige Säure (HOCl) für verschiedene Anwendungen verwendet, einschließlich Wundpflege, Augen-, Mund- und Nasenpflege, dermatologischen Erkrankungen, Podologie und Tiergesundheit. CEO Amy Trombly beschreibt die Partnerschaft als einen "großen Schritt nach vorne" für die Expansion des amerikanischen Wundpflegegeschäfts des Unternehmens.
Zusätzliche Einzelheiten zu der Vereinbarung sind im aktuellen Bericht von Sonoma auf dem Formular 8-K zu finden, der am 21. August 2024 bei der SEC eingereicht wurde.
- Partnership with a leading global healthcare distributor for U.S. market expansion
- Access to an extensive network of hospital systems and healthcare channels
- Potential for increased distribution and sales of wound care products
- None.
Insights
This partnership marks a significant expansion for Sonoma Pharmaceuticals in the U.S. wound care market. The collaboration with a leading global healthcare distributor could potentially increase Sonoma's market penetration and boost revenue streams. The extensive network of the distributor, covering hospital systems and various healthcare channels, provides Sonoma with a broader reach for its Microcyn® technology products.
However, the lack of specific financial details or distribution targets makes it challenging to quantify the immediate impact. Investors should monitor future earnings reports for concrete evidence of this partnership's effect on Sonoma's bottom line. The move aligns with industry trends of smaller biotech firms partnering with larger distributors to expand market access, potentially enhancing Sonoma's competitive position in the
While the news is positive, the lack of financial specifics limits our ability to project immediate revenue impact. Investors should look for updates in upcoming quarterly reports. Key metrics to watch include:
- Changes in revenue growth rate
- Gross margin improvements from potential economies of scale
- Selling, general and administrative (SG&A) expenses as a percentage of revenue
Sonoma's stock may see increased volatility as the market digests this news. The company's market cap of approximately
BOULDER, CO / ACCESSWIRE / August 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it has entered into a distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in the United States.
The agreement provides for the distribution of Sonoma's wound care products through an existing and extensive network of hospital systems and other healthcare channels in the United States.
"This partnership represents a huge step forward in the expansion of our wound care business in the United States," said Amy Trombly, CEO of Sonoma. "We are looking forward to working with a leading U.S.-based healthcare company, whose extensive distribution network will bring the benefits of our Microcyn technology to hospitals and other healthcare settings across the country."
Further information about the partnership can be found in the Current Report on Form 8-K filed by Sonoma with the U.S. Securities and Exchange Commission on August 21, 2024.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What new partnership did Sonoma Pharmaceuticals (SNOA) announce on August 21, 2024?
How will the new partnership benefit Sonoma Pharmaceuticals (SNOA)?
What is the core technology behind Sonoma Pharmaceuticals' (SNOA) products?
Where can investors find more information about Sonoma Pharmaceuticals' (SNOA) new distribution agreement?
